Baseline Clinical Characteristics and Incidence of Chronic Thromboembolic Pulmonary Hypertension Patients in Latvia, 2019–2020
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Gall, H.; Hoeper, M.M.; Richter, M.J.; Cacheris, W.; Hinzmann, B.; Mayer, E. An Epidemiological Analysis of the Burden of Chronic Thromboembolic Pulmonary Hypertension in the USA, Europe and Japan. Eur. Respir. Rev. 2017, 26, 160121. [Google Scholar] [CrossRef] [PubMed]
- Humbert, M.; Kovacs, G.; Hoeper, M.M.; Badagliacca, R.; Berger, R.M.F.; Brida, M.; Carlsen, J.; Coats, A.J.S.; Escribano-Subias, P.; Ferrari, P.; et al. 2022 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. Eur. Heart J. 2022, 43, 3618–3731. [Google Scholar] [CrossRef] [PubMed]
- Condon, D.F.; Nickel, N.P.; Anderson, R.; Mirza, S.; de Jesus Perez, V.A. The 6th World Symposium on Pulmonary Hypertension: What’s Old Is New. F1000Reaserch 2019, 8, F1000. [Google Scholar] [CrossRef] [PubMed]
- Galiè, N.; Humbert, M.; Vachiery, J.-L.; Gibbs, S.; Lang, I.; Torbicki, A.; Simonneau, G.; Peacock, A.; Vonk Noordegraaf, A.; Beghetti, M.; et al. 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur. Heart J. 2016, 37, 67–119. [Google Scholar] [CrossRef] [Green Version]
- Leber, L.; Beaudet, A.; Muller, A. Epidemiology of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: Identification of the Most Accurate Estimates from a Systematic Literature Review. Pulm. Circ. 2021, 11, 2045894020977300. [Google Scholar] [CrossRef]
- Hurdman, J.; Condliffe, R.; Elliot, C.A.; Davies, C.; Hill, C.; Wild, J.M.; Capener, D.; Sephton, P.; Hamilton, N.; Armstrong, I.J.; et al. ASPIRE Registry: Assessing the Spectrum of Pulmonary Hypertension Identified at a REferral Centre. Eur. Respir. J. 2012, 39, 945–955. [Google Scholar] [CrossRef] [Green Version]
- Peacock, A.J.; Murphy, N.F.; McMurray, J.J.V.; Caballero, L.; Stewart, S. An Epidemiological Study of Pulmonary Arterial Hypertension. Eur. Respir. J. 2007, 30, 104–109. [Google Scholar] [CrossRef] [Green Version]
- Schweikert, B.; Pittrow, D.; Vizza, C.D.; Pepke-Zaba, J.; Hoeper, M.M.; Gabriel, A.; Berg, J.; Sikirica, M. Demographics, Clinical Characteristics, Health Resource Utilization and Cost of Chronic Thromboembolic Pulmonary Hypertension Patients: Retrospective Results from Six European Countries. BMC Health Serv. Res. 2014, 14, 246. [Google Scholar] [CrossRef] [Green Version]
- Madani, M.; Ogo, T.; Simonneau, G. The Changing Landscape of Chronic Thromboembolic Pulmonary Hypertension Management. Eur. Respir. Rev. 2017, 26, 170105. [Google Scholar] [CrossRef]
- Population in Regions and Cities by Age and Gender at the Beginning of Year 1971–2022. Available online: https://data.stat.gov.lv:443/pxweb/en/OSP_PUB/START__POP__IR__IRD/IRD040/ (accessed on 4 July 2023).
- Skride, A.; Sablinskis, K.; Lejnieks, A.; Rudzitis, A.; Lang, I. Characteristics and Survival Data from Latvian Pulmonary Hypertension Registry: Comparison of Prospective Pulmonary Hypertension Registries in Europe. Pulm. Circ. 2018, 8, 2045894018780521. [Google Scholar] [CrossRef] [Green Version]
- Sablinskis, K.; Sablinskis, M.; Lejnieks, A.; Skride, A. Growing Number of Incident Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension Patients in Latvia: A Shifting Epidemiological Landscape? Data from a National Pulmonary Hypertension Registry. Eur. J. Intern. Med. 2019, 59, e16–e17. [Google Scholar] [CrossRef]
- Kigitovica, D.; Sablinskis, M.; Sablinskis, K.; Rudzitis, A.; Skride, A. Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension Incidence in Latvia in 2018. Eur. J. Intern. Med. 2019, 65, e9–e10. [Google Scholar] [CrossRef]
- Kopeć, G.; Dzikowska-Diduch, O.; Mroczek, E.; Mularek-Kubzdela, T.; Chrzanowski, Ł.; Skoczylas, I.; Tomaszewski, M.; Peregud-Pogorzelska, M.; Karasek, D.; Lewicka, E.; et al. Characteristics and Outcomes of Patients with Chronic Thromboembolic Pulmonary Hypertension in the Era of Modern Therapeutic Approaches: Data from the Polish Multicenter Registry (BNP-PL). Ther. Adv. Chronic. Dis. 2021, 12, 20406223211002960. [Google Scholar] [CrossRef]
- Demerouti, E.; Karyofyllis, P.; Voudris, V.; Boutsikou, M.; Anastasiadis, G.; Anthi, A.; Arvanitaki, A.; Athanassopoulos, G.; Avgeropoulou, A.; Brili, S.; et al. Epidemiology and Management of Chronic Thromboembolic Pulmonary Hypertension in Greece. Real-World Data from the Hellenic Pulmonary Hypertension Registry (HOPE). J. Clin. Med. 2021, 10, 4547. [Google Scholar] [CrossRef]
- Rådegran, G.; Kjellström, B.; Ekmehag, B.; Larsen, F.; Rundqvist, B.; Blomquist, S.B.; Gustafsson, C.; Hesselstrand, R.; Karlsson, M.; Kornhall, B.; et al. Characteristics and Survival of Adult Swedish PAH and CTEPH Patients 2000–2014. Scand. Cardiovasc. J. 2016, 50, 243–250. [Google Scholar] [CrossRef]
- Kramm, T.; Wilkens, H.; Fuge, J.; Schäfers, H.-J.; Guth, S.; Wiedenroth, C.B.; Weingard, B.; Huscher, D.; Pittrow, D.; Cebotari, S.; et al. Incidence and Characteristics of Chronic Thromboembolic Pulmonary Hypertension in Germany. Clin. Res. Cardiol. 2018, 107, 548–553. [Google Scholar] [CrossRef] [Green Version]
- Health Behaviour among Latvian Adult Population, 2020|Slimību Profilakses un Kontroles Centrs. Available online: https://www.spkc.gov.lv/lv/veselibu-ietekmejoso-paradumu-petijumi (accessed on 21 April 2023).
- Krieg, V.J.; Hobohm, L.; Liebetrau, C.; Guth, S.; Kölmel, S.; Troidl, C.; Mayer, E.; Konstantinides, S.V.; Wiedenroth, C.B.; Lankeit, M. Risk Factors for Chronic Thromboembolic Pulmonary Hypertension–Importance of Thyroid Disease and Function. Thromb. Res. 2020, 185, 20–26. [Google Scholar] [CrossRef] [Green Version]
- Kim, N.H.; Lang, I.M. Risk Factors for Chronic Thromboembolic Pulmonary Hypertension. Eur. Respir. Rev. 2012, 21, 27–31. [Google Scholar] [CrossRef]
- Pepke-Zaba, J.; Delcroix, M.; Lang, I.; Mayer, E.; Jansa, P.; Ambroz, D.; Treacy, C.; D’Armini, A.M.; Morsolini, M.; Snijder, R.; et al. Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Results from an International Prospective Registry. Circulation 2011, 124, 1973–1981. [Google Scholar] [CrossRef] [Green Version]
- Donaldson, S.; Ogunti, R.; Kibreab, A.; Mehari, A. Riociguat in the Treatment of Chronic Thromboembolic Pulmonary Hypertension: An Evidence-Based Review of Its Place in Therapy. Core Evid. 2020, 15, 31–40. [Google Scholar] [CrossRef]
- Bunclark, K.; Newnham, M.; Chiu, Y.-D.; Ruggiero, A.; Villar, S.S.; Cannon, J.E.; Coghlan, G.; Corris, P.A.; Howard, L.; Jenkins, D.; et al. A Multicenter Study of Anticoagulation in Operable Chronic Thromboembolic Pulmonary Hypertension. J. Thromb. Haemost. 2020, 18, 114–122. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wilkens, H.; Konstantinides, S.; Lang, I.M.; Bunck, A.C.; Gerges, M.; Gerhardt, F.; Grgic, A.; Grohé, C.; Guth, S.; Held, M.; et al. Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Updated Recommendations from the Cologne Consensus Conference 2018. Int. J. Cardiol. 2018, 272S, 69–78. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Baseline Characteristics | All CTEPH Patients (n = 13), Median ± IQR | CTEPH in 2019 (n = 6), Median ± IQR | CTEPH in 2020 (n = 7), Median ± IQR |
---|---|---|---|
Age, years | 67.0 ± 17.0 | 57.0 ± 18.5 | 68.0 ± 9.5 |
Female/male ratio | 2.25 | 2 | 2.5 |
BMI, kg/m2 | 24.0 ± 7.0 | 25.5 ± 9.2 | 23.6 ± 6.2 |
BNP, pg/ml | 582.00 ± 525.45 | 449.50 ± 464.69 | 586.65 ± 631.57 |
SpO2, % | 97.0 ± 1.0 | 96.5 ± 1.0 | 97.0 ± 5.0 |
Functional status | |||
WHO FC n, | |||
I | 0 | 0 | 0 |
II | 3 | 1 | 2 |
III | 8 | 5 | 3 |
IV | 2 | 0 | 2 |
6 MWD, m | 300.0 ± 150.0 (n = 11) | 285.0 ± 52.5 | 420.0 ± 165.0 (n = 5) |
Right heart catheterization | |||
mPAP, mmHg | 40.0 ± 13.0 | 41.5 ± 10.5 | 39.0 ± 14.5 |
RAP, mmHg | 3.0 ± 4.0 | 3.0 ± 3.5 | 3.0 ± 3.0 |
PVR, WU | 7.35 ± 2.82 (n = 12) | 8.67 ± 5.27 (n = 5) | 6.80 ± 2.81 |
PCWP, mmHg | 10.0 ± 8.5 (n = 12) | 10.0 ± 0.0 (n = 5) | 15.0 ± 9.0 |
CI, l/min/m2 ± SD | 2.06 ± 0.70 (n = 12) | 1.86 ± 0.54 (n = 5) | 2.28 ± 0.67 |
CO, l/min ± SD | 3.73 ± 2.06 (n = 12) | 3.20 ± 2.04 (n = 5) | 3.87 ± 2.04 |
CTEPH Risk Factor | All CTEPH Patients, n | CTEPH Patients in 2019, n | CTEPH Patients in 2020, n |
---|---|---|---|
History of venous thromboembolism | 11 | 6 | 5 |
History of acute pulmonary embolism | 10 | 5 | 5 |
History of deep vein thrombosis | 3 | 2 | 1 |
Recurrence of pulmonary embolism | 3 | 2 | 1 |
Chronic inflammatory disease | 0 | 0 | 0 |
Atrial septal defect | 0 | 0 | 0 |
VA shunt | 0 | 0 | 0 |
History of splenectomy | 1 | 0 | 1 |
Antiphospholipid syndrome | 0 | 0 | 0 |
History of malignancy | 3 | 1 | 2 |
Blood type | |||
O | 3 | 1 | 2 |
A | 4 | 2 | 2 |
B | 6 | 3 | 3 |
AB | 0 | 0 | 0 |
Smoking | 4 | 2 | 2 |
Concomitant Diseases | All CTEPH Patients, n | CTEPH Patients in 2019, n | CTEPH Patients in 2020, n |
---|---|---|---|
Coronary artery disease | 8 | 4 | 4 |
Systemic arterial hypertension | 6 | 2 | 4 |
Dyslipidemia | 6 | 4 | 2 |
Thyroid disease | 5 | 2 | 3 |
Atrial fibrillation | 2 | 1 | 1 |
Chronic kidney disease | 2 | 0 | 2 |
Chronic obstructive pulmonary disease | 2 | 1 | 1 |
Diabetes | 0 | 0 | 0 |
Obstructive sleep apnea | 0 | 0 | 0 |
PAH-specific treatment | |||
PDE5i | 13 | 6 | 7 |
Endothelin receptor antagonist | 1 | 0 | 1 |
Treatment | |||
Beta blockers | 9 | 5 | 4 |
ACEI | 3 | 1 | 2 |
ARB | 1 | 0 | 1 |
Potassium-sparing diuretics | 13 | 6 | 7 |
Loop diuretics | 9 | 3 | 6 |
Thiazide diuretics | 0 | 0 | 0 |
Ivabradine | 7 | 4 | 3 |
Statins | 9 | 4 | 5 |
Anticoagulant | |||
Vitamin K antagonists | 8 | 3 | 5 |
New oral anticoagulants | 5 | 3 | 2 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kauliņš, R.; Rudzītis, A.; Lejnieks, A.; Kigitoviča, D.; Skride, A. Baseline Clinical Characteristics and Incidence of Chronic Thromboembolic Pulmonary Hypertension Patients in Latvia, 2019–2020. Medicina 2023, 59, 1426. https://doi.org/10.3390/medicina59081426
Kauliņš R, Rudzītis A, Lejnieks A, Kigitoviča D, Skride A. Baseline Clinical Characteristics and Incidence of Chronic Thromboembolic Pulmonary Hypertension Patients in Latvia, 2019–2020. Medicina. 2023; 59(8):1426. https://doi.org/10.3390/medicina59081426
Chicago/Turabian StyleKauliņš, Ričards, Ainārs Rudzītis, Aivars Lejnieks, Dana Kigitoviča, and Andris Skride. 2023. "Baseline Clinical Characteristics and Incidence of Chronic Thromboembolic Pulmonary Hypertension Patients in Latvia, 2019–2020" Medicina 59, no. 8: 1426. https://doi.org/10.3390/medicina59081426